These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7712122)

  • 1. Design of orally bioavailable, symmetry-based inhibitors of HIV protease.
    Kempf DJ; Marsh KC; Fino LC; Bryant P; Craig-Kennard A; Sham HL; Zhao C; Vasavanonda S; Kohlbrenner WE; Wideburg NE
    Bioorg Med Chem; 1994 Sep; 2(9):847-58. PubMed ID: 7712122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
    Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
    J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moiety.
    Billich A; Fricker G; Müller I; Donatsch P; Ettmayer P; Gstach H; Lehr P; Peichl P; Scholz D; Rosenwirth B
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1406-13. PubMed ID: 7492076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
    Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
    J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
    Dorsey BD; Levin RB; McDaniel SL; Vacca JP; Guare JP; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC
    J Med Chem; 1994 Oct; 37(21):3443-51. PubMed ID: 7932573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.
    Ghosh AK; McKee SP; Sanders WM; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC; Huff JR; Anderson PS
    Drug Des Discov; 1993; 10(1):77-88. PubMed ID: 8399995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, antiviral activity, and bioavailability studies of gamma-lactam derived HIV protease inhibitors.
    Hungate RW; Chen JL; Starbuck KE; Vacca JP; McDaniel SL; Levin RB; Dorsey BD; Guare JP; Holloway MK; Whitter W
    Bioorg Med Chem; 1994 Sep; 2(9):859-79. PubMed ID: 7712123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
    Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg NE; Kempf D; Norbeck DW; Plattner JJ
    Biochem Biophys Res Commun; 1996 Aug; 225(2):436-40. PubMed ID: 8753780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
    Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
    J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
    Duffy JL; Rano TA; Kevin NJ; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2569-72. PubMed ID: 12852968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.
    Kim CU; McGee LR; Krawczyk SH; Harwood E; Harada Y; Swaminathan S; Bischofberger N; Chen MS; Cherrington JM; Xiong SF; Griffin L; Cundy KC; Lee A; Yu B; Gulnik S; Erickson JW
    J Med Chem; 1996 Aug; 39(18):3431-4. PubMed ID: 8784440
    [No Abstract]   [Full Text] [Related]  

  • 14. 2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors.
    Beaulieu PL; Anderson PC; Cameron DR; Croteau G; Gorys V; Grand-Maître C; Lamarre D; Liard F; Paris W; Plamondon L; Soucy F; Thibeault D; Wernic D; Yoakim C; Pav S; Tong L
    J Med Chem; 2000 Mar; 43(6):1094-108. PubMed ID: 10737742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol.
    Kempf DJ; Codacovi L; Wang XC; Kohlbrenner WE; Wideburg NE; Saldivar A; Vasavanonda S; Marsh KC; Bryant P; Sham HL
    J Med Chem; 1993 Feb; 36(3):320-30. PubMed ID: 8426362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands.
    Chen X; Kempf DJ; Li L; Sham HL; Vasavanonda S; Wideburg NE; Saldivar A; Marsh KC; McDonald E; Norbeck DW
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3657-60. PubMed ID: 14552751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
    Zhang F; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2573-6. PubMed ID: 12852969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR.
    Barrish JC; Gordon E; Alam M; Lin PF; Bisacchi GS; Chen P; Cheng PT; Fritz AW; Greytok JA; Hermsmeier MA
    J Med Chem; 1994 Jun; 37(12):1758-68. PubMed ID: 8021916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.
    Bold G; Fässler A; Capraro HG; Cozens R; Klimkait T; Lazdins J; Mestan J; Poncioni B; Rösel J; Stover D; Tintelnot-Blomley M; Acemoglu F; Beck W; Boss E; Eschbach M; Hürlimann T; Masso E; Roussel S; Ucci-Stoll K; Wyss D; Lang M
    J Med Chem; 1998 Aug; 41(18):3387-401. PubMed ID: 9719591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.